Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Daniel Pollyea to DNA Methylation

This is a "connection" page, showing publications Daniel Pollyea has written about DNA Methylation.

 
Connection Strength
 
 
 
0.873
 
  1. Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019 12; 33(12):2795-2804.
    View in: PubMed
    Score: 0.411
  2. Garcia JS, Desai P, Zeidner JF, Wolach O, LeBlanc TW, Abedin S, Vachhani P, Sweet K, Moshe Y, Pollyea DA, Lai C, Levitz D, Nachmias B, Mozessohn L, Xavier M, Zuckerman T, Konopleva M, Chen EC, Stahl M, Xu Y, Bui CN, Miu K, Schmidt X, Grunspan M, Lin CW, Ma E, Montez M, Guérin A, Burne R, Easson K, Levesque-Leroux M, Baraka E, Goldberg AD. Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study. Leuk Lymphoma. 2026 Sep; 67(11):2282-2294.
    View in: PubMed
    Score: 0.164
  3. Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, ?ucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 09; 44(25):2422-2434.
    View in: PubMed
    Score: 0.163
  4. Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frankhouser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015 Jun; 25(6):707-25.
    View in: PubMed
    Score: 0.075
  5. Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012 May; 26(5):893-901.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)